Isosorbide 5 mononitrate administration increases nitric oxide blood levels and reduces proteinuria in IgA glomerulonephritis patients with abnormal urinary endothelin/cyclic GMP ratio.
An endothelin urinary hyperexcretion, which is not counterbalanced by an adequate increase in cGMP biosynthesis, was previously detected in some patients with IgA Nephropathy (IgAN). Since this imbalance might potentiate local ET1-mediated hemodynamics effects, 9 IgAN patients with an increased (> or = 0.1) urinary ET1/cGMP ratio (group 1) and 5 IgAN patients with comparable renal function and reduced ET1/cGMP ratio (group 2) were given standard doses of isosorbide 5 mononitrate (as a nitric oxide source). Blood nitric oxide (NO) levels, as detected by electron paramagnetic resonance, significantly increased after isosorbide administration (p < 0.01) and decreased after drug discontinuation in both groups. Nitric oxide levels were significantly related with those of the effective renal plasma flow (p < 0.02), but not with the glomerular filtration rate. Proteinuria levels significantly decreased after drug administration (p < 0.009) in group 1 and returned to baseline levels thereafter, except two cases showing persisting low levels. Values of filtration fraction in the same group decreased after iso5M administration (p < 0.02 compared to basal levels). These results may possibly be related to the counterbalancing effects of nitric oxide on endothelin-mediated mesangial contraction.
Roccatello
D
D
Istituto di Nefrourologia, Università di Torino, Italy.
Mengozzi
G
G
Ferro
M
M
Cesano
G
G
Polloni
R
R
Mosso
R
R
Bonetti
G
G
Inconis
T
T
Paradisi
L
L
Sena
L M
LM
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D006152:Cyclic GMP / Q000652:urine*; D004578:Electron Spin Resonance Spectroscopy; D016232:Endothelins / Q000652:urine*; D005260:Female; D005922:Glomerulonephritis, IGA / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use*
D016232:Endothelins; D014665:Vasodilator Agents; D009569:Nitric Oxide; D006152:Cyclic GMP; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate